Company intelligence / Profile preview

DeepSeq.AI

Fremont, California, United Statesdeepseq.ai ↗

Ownership: Private
Development stage: Preclinical

Overview

DeepSeq.AI has developed an explainable generative AI platform that enables large-scale, high-throughput protein library design and functional screening. The company collaborates with pharmaceutical partners to accelerate the identification of novel protein therapeutics. It has received recognition through grants (NSF SBIR Phase I), government contracts (DARPA), and industry partnerships (Gilead Technology Evaluation Agreement). No clinical results are reported as the focus is on enabling R&D rather than advancing proprietary therapeutic candidates.

Therapeutic areas: Other
Modalities: Protein therapeuticsNanobodies
Industry: Drug Discovery Services

Partnerships

Gilead Sciences (technology evaluation agreement regarding protein therapeutic design)DARPA contract recipient under its AI BTO Pitch Day Initiative

Beyond the preview

Go deeper on DeepSeq.AI.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DeepSeq.AI.

Explore the full profile